Blackstone and CPP Investments completed the acquisition of a majority stake in Advarra from Genstar Capital and Linden Capital for $5bn.

Blackstone, an American multinational private equity, and Canada Pension Plan Investment Board, a global investment management organization, completed the acquisition of a majority stake in Advarra, a provider of regulatory, quality, and compliance solutions and clinical trial technologies, from private equity firms Genstar Capital and Linden Capital, for $5bn. “We are proud to back Advarra given its important role in enabling high-quality clinical R&D and helping its clients bring life-changing treatments to patients. Sustained innovation and scientific advancement in life sciences is one of our highest conviction investment themes across Blackstone. We are excited to partner with Gadi and the rest of the Advarra team to continue investing in talent, differentiated scientific expertise, customer-centric solutions, and innovative clinical trial technology to realize Advarra’s full potential in the years ahead," Anushka Sunder, Blackstone Senior Managing Director.